Cardiff Oncology, Inc.
CRDF
$1.05
-$0.05-4.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 21.50% | 8.38% | -0.92% | -17.31% | -24.87% |
| Total Depreciation and Amortization | -3.68% | -4.06% | -4.14% | 11.90% | 34.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.98% | 17.23% | 16.41% | 25.34% | 41.09% |
| Change in Net Operating Assets | -281.56% | 68.53% | -17.24% | -33.91% | -26.16% |
| Cash from Operations | 2.37% | 12.47% | -0.61% | -22.16% | -30.50% |
| Capital Expenditure | -138.46% | -- | 45.00% | 50.00% | 93.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 249.19% | 450.09% | -89.96% | -121.22% | -167.14% |
| Cash from Investing | 248.78% | 449.29% | -90.22% | -121.49% | -167.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -94.39% | -95.00% | -95.20% | 360.97% | 2,284.20% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -94.51% | -95.00% | -95.20% | 360.97% | 2,284.20% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 89.22% | -386.02% | -214.04% | -32.26% | -340.00% |